Understanding how ULK3 affects multiple myeloma treatment resistance
Role of ULK3 in Sensitive and Refractory Multiple Myeloma
This study is looking at a protein called ULK3 to understand how it helps multiple myeloma cells survive and resist treatments, with the goal of creating new medicines that could work better for patients whose cancer is hard to treat.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10979173 on NIH RePORTER |
What this research studies
This research investigates the role of a specific protein, ULK3, in multiple myeloma, a type of blood cancer that is often resistant to treatment. By analyzing genetic data from patients, the team aims to uncover how ULK3 contributes to the survival of cancer cells and their resistance to therapies like bortezomib. The researchers are also developing new inhibitors that target ULK3 and other related proteins to improve treatment outcomes for patients with refractory disease. This approach could lead to more effective therapies that provide longer-lasting responses for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma, particularly those who have experienced treatment resistance.
Not a fit: Patients with early-stage multiple myeloma who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that overcome resistance in multiple myeloma, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Lynch, Conor C — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Lynch, Conor C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.